36 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
Rank Status Study
21 Recruiting Fresolimumab and Radiotherapy in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008);   Radiation: Radiation Therapy
22 Completed The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
Condition: Kidney Transplantation
Intervention:
23 Terminated A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Pleneva TM BGC20-0134;   Drug: Placebo
24 Active, not recruiting Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients
Condition: Osteosarcoma
Intervention:
25 Completed Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata
Condition: Alopecia Areata
Interventions: Radiation: ultraviolet A (UVA);   Drug: Triamcinolone Acetonide
26 Completed Study of Sodium Bicarbonate in Kidney Transplant Recipients
Condition: Kidney Transplantation
Intervention: Drug: Sodium bicarbonate
27 Completed Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
Conditions: Cicatrix;   Wound Healing
Interventions: Drug: Avotermin;   Drug: Placebo (vehicle)
28 Completed Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
Conditions: Cicatrix;   Wound Healing
Interventions: Drug: Avotermin;   Drug: Placebo
29 Completed Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
Conditions: Cicatrix;   Wound Healing
Interventions: Drug: Intradermal avotermin;   Drug: Placebo (vehicle);   Drug: Placebo
30 Completed Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)
Conditions: Cicatrix;   Wound Healing;   Re-epithelialization
Interventions: Drug: Avotermin;   Drug: Placebo
31 Completed Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects
Conditions: Cicatrix;   Wound Healing
Interventions: Drug: Avotermin;   Drug: Placebo
32 Recruiting Study of Arimidex and Radiotherapy Sequencing
Condition: Breast Cancer
Interventions: Drug: Pre-radiotherapy commencement of Arimidex;   Drug: Post radiotherapy commencement of Arimidex;   Radiation: Radiotherapy
33 Active, not recruiting A Study in Patients With Diabetic Kidney Disease
Conditions: Diabetic Kidney Disease;   Diabetic Nephropathy;   Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770;   Drug: Placebo
34 Completed Cytokine Gene Polymorphisms in Bone Marrow Failure
Condition: Bone Marrow Diseases
Intervention:
35 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
36 Completed Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
Condition: Cicatrix
Intervention: Drug: Juvista (avotermin) plus placebo, standard-care (within-subject controls)

Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page
Indicates status has not been verified in more than two years